<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Affiliated Computer Services Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/affiliated-computer-services-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(XRX) Xerox Buys The Breakaway Group</title>
		<link>http://www.stockbloghub.com/2011/12/01/xrx-xerox-buys-the-breakaway-group/87797</link>
		<comments>http://www.stockbloghub.com/2011/12/01/xrx-xerox-buys-the-breakaway-group/87797#comments</comments>
		<pubDate>Thu, 01 Dec 2011 14:58:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Business Equipment]]></category>
		<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Emerson Electric Company]]></category>
		<category><![CDATA[EMR]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87797</guid>
		<description><![CDATA[Xerox Corp. (XRX) recently announced that one of its fully owned subsidiaries, Affiliated Computer Services (ACS), has acquired The Breakaway Group with the sole intent of expanding its electronic medical records business.  The terms of the deal along with its financial terms remain undisclosed. Denver-based The Breakaway Group is a cloud-computing company which offers a technology called PromisePoint. Alongside the popular training program it provides, it helps healthcare professionals to learn the usage of electronic methods and adopt the updated versions of Electronic Medical Records (EMR) in a simulated environment. According to Xerox, the acquisition will enable the company’s medical industry clients to improve and customize their record systems for different hospitals, patients and doctors, without risking the actual data set. It will also enable the users to prepare for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/xrx-xerox-buys-the-breakaway-group/87797/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WSH) Willis Group Buys Stake in South Africa</title>
		<link>http://www.stockbloghub.com/2011/04/08/wsh-willis-group-buys-stake-in-south-africa/70961</link>
		<comments>http://www.stockbloghub.com/2011/04/08/wsh-willis-group-buys-stake-in-south-africa/70961#comments</comments>
		<pubDate>Fri, 08 Apr 2011 20:42:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Insurance Brokers]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AJG]]></category>
		<category><![CDATA[Arthur J Gallagher & Company]]></category>
		<category><![CDATA[Marsh & McLennan Companies Inc]]></category>
		<category><![CDATA[MMC]]></category>
		<category><![CDATA[Willis Group Holdings Limited]]></category>
		<category><![CDATA[WSH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70961</guid>
		<description><![CDATA[Willis Europe BV, a division of  Willis Group Holdings plc (WSH), announced that Willis South Africa has acquired 22.5% of the equity in Amabubesi Consulting Services (ACS). ACS, a specialist employee benefits consulting business, is part of the Amabubesi Group, a South African investment company. Earlier, in August 2009, Amabubesi acquired a 26% stake in Willis South Africa. Also,  Peter Moyo, Executive Director of Amabubesi, and Ndivhuwo Ravele, former CEO of ACS, have joined the board of Willis South Africa as Non-Executive Directors; and Ryck Genis, CEO of Willis South Africa, has joined the board of ACS. The joining of the top executives of one company to the board of other is expected to create synergies between the companies. Wllis believes South Africa offers excellent long-term growth potential as it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/wsh-willis-group-buys-stake-in-south-africa/70961/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Announces Response to FDA Complete Response Letter</title>
		<link>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664</link>
		<comments>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:48:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65664</guid>
		<description><![CDATA[AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided additional analyses of the Study of Platelet Inhibition and Patient Outcomes (PLATO) as requested by the FDA. AstraZeneca is looking to get Brilinta approved for the treatment of acute coronary syndrome (ACS). CRL Issued in Dec 2010 The FDA had issued a CRL on Dec 16, 2010 for Brilinta. At that time, the agency had asked AstraZeneca to conduct additional analyses of data from the PLATO trial. The trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). The company said that the additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab</title>
		<link>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405</link>
		<comments>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405#comments</comments>
		<pubDate>Wed, 22 Dec 2010 21:07:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63405</guid>
		<description><![CDATA[AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the Biological License Application (BLA) for the candidate. AstraZeneca expects to incur an impairment charge of $445 million in the fourth quarter of 2010 due to the discontinuation of the development of the candidate. The impairment charge, however, is not expected to impact the company’s core earnings. Rough Regulatory Path for Motavizumab AstraZeneca’s decision does not come as a major surprise as the regulatory process for motavizumab has been rocky. Earlier this year, the FDA’s Antiviral Drugs Advisory Committee had voted against the approval of motavizumab for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers FDA Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756</link>
		<comments>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756#comments</comments>
		<pubDate>Sat, 18 Dec 2010 20:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62756</guid>
		<description><![CDATA[AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the use of Brilinta in the treatment of acute coronary syndrome (ACS). The agency has asked AstraZeneca to conduct additional analyses of data from the Study of Platelet Inhibition and Patient Outcomes (PLATO). The PLATO trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). Importantly, AstraZeneca has not been asked to conduct additional studies which could have delayed the approval process even further. The additional delay in Brilinta’s approval is a big disappointment for AstraZeneca which has been banking on Brilinta&#8217;s approval to help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Receives Good Patent News</title>
		<link>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847</link>
		<comments>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847#comments</comments>
		<pubDate>Fri, 10 Dec 2010 20:18:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=61847</guid>
		<description><![CDATA[We recently reiterated our Outperform recommendation on The Medicines Company (MDCO). In August 2010, The Medicines Company received good news with the US District Court for the Eastern District of Virginia ordering the US Patent and Trademark Office (PTO) to treat The Medicines Company’s patent term extension application for lead product, Angiomax, as having been filed on a timely basis. Following this ruling, the PTO granted a one-year interim extension of the principal US patent that covers Angiomax. The extension will provide exclusivity until August 13, 2011 (February 2012 including 6-month pediatric exclusivity). With the US Solicitor General and the Government deciding against appealing the Court’s ruling, a major overhang on The Medicines Company has been removed. Previously, we were expecting Angiomax to start facing generics from late 2010. But, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/10/mdco-the-medicines-company-receives-good-patent-news/61847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Earnings Well Above on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953</link>
		<comments>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:34:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56953</guid>
		<description><![CDATA[The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus Estimate of 24 cents and the year-ago loss of 6 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, although up 6.9% at $105.7 million, fell short of the Zacks Consensus Estimate of $110 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter. Angiomax sales in the US increased 9% to $100.2 million with Angiomax box sales increasing 14% from the year-ago period. EU sales increased 38% to $4 million mainly due to strong growth in countries like Italy, Switzerland, Spain, France, Scandinavia, and the United Kingdom. RoW sales, however, declined 42% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/mdco-the-medicines-company-earnings-well-above-on-lower-costs/56953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Shares Uppgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526</link>
		<comments>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526#comments</comments>
		<pubDate>Tue, 12 Oct 2010 14:29:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54526</guid>
		<description><![CDATA[We recently upgraded The Medicines Company (MDCO) to Outperform based on our improved outlook on the stock. In August 2010, The Medicines Company received good news when the US District Court for the Eastern District of Virginia ordered the US Patent and Trademark Office (PTO) to treat the company’s patent term extension application for lead product Angiomax as having been filed on a timely basis. Following this ruling, the PTO granted a one-year interim extension of the principal US patent that covers Angiomax. The extension will provide exclusivity until August 13, 2011 (February 2012 including 6-month pediatric exclusivity). With the US Solicitor General and the Government deciding against appealing the Court’s ruling, a major overhang on The Medicines Company has been removed. Previously, we were expecting Angiomax to start facing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/mdco-the-medicines-company-shares-uppgraded-to-outperform/54526/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758</link>
		<comments>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758#comments</comments>
		<pubDate>Mon, 27 Sep 2010 05:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52758</guid>
		<description><![CDATA[Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA approval to use the assay to test urine specimens from men who earlier had a negative prostate biopsy. This represents the second of the four PMA submissions that Gen-Probe plans to complete in 2010. The FDA has formally accepted the PROGENSA PMA and has advised Gen-Probe that a meeting (timeline unspecified) of the Medical Devices Advisory Committee&#8217;s Immunology Panel will be necessary to support approval of the filling. Gen-Probe acquired the exclusive global rights to the PCA3 (a genetic marker for prostate cancer) from Canadian cancer diagnostic tests ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Affiliated Computer Services / Xerox Merger Approved</title>
		<link>http://www.stockbloghub.com/2010/02/08/acs-affiliated-computer-services-xerox-merger-approved/27321</link>
		<comments>http://www.stockbloghub.com/2010/02/08/acs-affiliated-computer-services-xerox-merger-approved/27321#comments</comments>
		<pubDate>Mon, 08 Feb 2010 18:12:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Urban Outfitters Inc.]]></category>
		<category><![CDATA[URBN]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27321</guid>
		<description><![CDATA[Affiliated Computer Services Inc. (ACS), a leading business process outsourcing firm rose 0.45% after hours Friday, after falling 2.28% to close at $59.64 following the company’s announcement that shareholders had approved its acquisition by Xerox Corporation (XRX). XRX shares are down slightly in early trading Monday. The transaction is expected to close soon and as a result, Standard &#38; Poor’s announced changes to its index. S&#38;P MidCap 400 constituent Urban Outfitters Inc. (URBN) will replace ACS in the S&#38;P 500 index. In September, Xerox agreed to acquire Affiliated in a cash and stock transaction valued at $6.4 billion ($63.11 per ACS share in cash and Xerox stock as of the closing price of Xerox on September 25). Affiliated shareholders would receive $18.60 per share in cash and 4.935 shares of Xerox. Xerox would also assume ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/acs-affiliated-computer-services-xerox-merger-approved/27321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Affiliated Computer Services Beats Forecasts on Strong New Signings</title>
		<link>http://www.stockbloghub.com/2010/01/23/acs-affiliated-computer-services-beats-forecasts-on-strong-new-signings/25797</link>
		<comments>http://www.stockbloghub.com/2010/01/23/acs-affiliated-computer-services-beats-forecasts-on-strong-new-signings/25797#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:00:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25797</guid>
		<description><![CDATA[Operating Performance Affiliated Computer Services, Inc. (ACS) reported second-quarter 2010 pro forma earnings of $1.07 per share, an increase of 25.9% from 85 cents reported in the year-ago period. Earnings for the quarter beat the Zacks Consensus Estimate of 99 cents a share by 8 cents. Adjusted non-GAAP operating income was $182.8 million or 11.0% of total revenue in the quarter, compared to $172.6 million or 10.7% of total revenue in the year-ago period. The quarter benefited from new business and renewed contracts. Revenue Total revenue increased 2.7% to $1.66 billion from the year-ago quarter. The entire increase was attributed to acquisitions. The Commercial segment was particularly strong, while Government was flat year over year. The Commercial segment contributed 61% of revenues and grew 5% year over year, with internal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/acs-affiliated-computer-services-beats-forecasts-on-strong-new-signings/25797/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Affiliated Computer Services Shareholders Able to Vote on Purchase by Xerox</title>
		<link>http://www.stockbloghub.com/2009/12/30/acs-affiliated-computer-services-shareholders-able-to-vote-on-xerox-purchase-of-them/23939</link>
		<comments>http://www.stockbloghub.com/2009/12/30/acs-affiliated-computer-services-shareholders-able-to-vote-on-xerox-purchase-of-them/23939#comments</comments>
		<pubDate>Wed, 30 Dec 2009 21:44:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23939</guid>
		<description><![CDATA[Affiliated Computer Services Inc. (ACS), a leading business process outsourcing firm, and Xerox Corporation (XRX) announced that shareholders will have the right to vote on Xerox’s agreement to buy ACS. Shareholders of both the companies on record as of Dec. 11 will be able to vote on the merger in a special meeting scheduled for Feb. 5, 2010. In September, Xerox agreed to acquire Affiliated in a cash and stock transaction valued at $6.4 billion ($63.11 per ACS share in cash and Xerox stock as of the closing price of Xerox on September 25). Affiliated shareholders would receive $18.60 per share in cash and 4.935 shares of Xerox. Xerox would also assume $2 billion of ACS’s debt and would issue $300 million of convertible preferred stock to ACS’s shareholders. For ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/30/acs-affiliated-computer-services-shareholders-able-to-vote-on-xerox-purchase-of-them/23939/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Affiliated Computer Services Extends IT Contract</title>
		<link>http://www.stockbloghub.com/2009/12/29/acs-affiliated-computer-services-extends-it-contract/23826</link>
		<comments>http://www.stockbloghub.com/2009/12/29/acs-affiliated-computer-services-extends-it-contract/23826#comments</comments>
		<pubDate>Tue, 29 Dec 2009 19:08:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Cognizant Technology Solutions]]></category>
		<category><![CDATA[Computer Sciences Corporation]]></category>
		<category><![CDATA[CSC]]></category>
		<category><![CDATA[CTSH]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23826</guid>
		<description><![CDATA[Affiliated Computer Services, Inc. (ACS) announced an extension of a three-year information technology (IT) contract through 2015 with DCP Midstream, a Denver-based energy company. The contract is worth $72 million. Based in Dallas, ACS delivers comprehensive business process outsourcing (BPO) and IT outsourcing solutions as well as system integration services globally to commercial and government clients. ACS will provide DCP with customized IT solutions such as end user and desktop support, midrange and network services, messaging services, document management, security services and application services and disaster recovery services. Additionally, ACS will help DCP with evaluating and implementing new technologies such as virtual desktop and provide additional IT services including, Telecommunication Expense Management Services (TEMS). ACS will also provide additional application support and security services. These services will help DCP achieve ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/acs-affiliated-computer-services-extends-it-contract/23826/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVL) Novell Completes Business Unit Reorganization</title>
		<link>http://www.stockbloghub.com/2009/12/17/novl-novell-completes-business-unit-reorganization/23141</link>
		<comments>http://www.stockbloghub.com/2009/12/17/novl-novell-completes-business-unit-reorganization/23141#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:06:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Security Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Novell Inc.]]></category>
		<category><![CDATA[NOVL]]></category>
		<category><![CDATA[SAP]]></category>
		<category><![CDATA[Sap Ag]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23141</guid>
		<description><![CDATA[Novell Inc. (NOVL), a leading technology software company, announced consolidation of its 4 business units into 2 to better streamline its business and focus on core operations. The company’s Identity and Security Management (ISM), Systems and Resource Management (SRM) and Open Platform Solutions (OPS) business units will be incorporated into the new Security, Management and Operating Platforms business unit. The reorganization of the business units is expected to take place from Jan 1, 2010. To better conduct these operations, the company also shuffled management positions. Jim Ebzery, the Senior Vice President and general manager of identity and security management will become the head of the new unit. The reorganization of its structure and management will better align Novell’s business and help the company become the leader in the emerging Intelligent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/novl-novell-completes-business-unit-reorganization/23141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVL) Novell&#8217;s Earnings Beat Expectations</title>
		<link>http://www.stockbloghub.com/2009/12/04/novl-novells-earnings-beat-expectations/22055</link>
		<comments>http://www.stockbloghub.com/2009/12/04/novl-novells-earnings-beat-expectations/22055#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:29:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Security Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Novell Inc.]]></category>
		<category><![CDATA[NOVL]]></category>
		<category><![CDATA[SAP]]></category>
		<category><![CDATA[Sap Ag]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22055</guid>
		<description><![CDATA[A leading technology software company, Novell, Inc. (NOVL) reported fourth-quarter earnings that beat the Zacks Consensus Estimates. Although revenue declined, earnings were up from the year-ago period. Excluding the non-cash goodwill and intangible assets impairment charge of $279 million, adjusted EPS (non-GAAP) came in at 11 cents in the quarter and beat the Zacks Consensus Estimate of 6 cents. Non-GAAP EPS increased 83.3% from the 6 cents reported in the year-ago period due to cost-cutting efforts. As a result of lower operating expenses (sales and marketing fell 24.3% and product and development expenses fell 9.3% year over year) non-GAAP operating margin improved to 17.2% in the quarter from 13.1% in the year-ago quarter. The company plans to reach its long-term goal of generating 20% in operating margin and expects top-line ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/novl-novells-earnings-beat-expectations/22055/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NOVL) Earnings Preview: Novell</title>
		<link>http://www.stockbloghub.com/2009/12/03/novl-earnings-preview-novell/21876</link>
		<comments>http://www.stockbloghub.com/2009/12/03/novl-earnings-preview-novell/21876#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:07:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Security Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[DELL]]></category>
		<category><![CDATA[Dell Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Novell Inc.]]></category>
		<category><![CDATA[NOVL]]></category>
		<category><![CDATA[Oracle Corporation]]></category>
		<category><![CDATA[ORCL]]></category>
		<category><![CDATA[Red Hat Inc.]]></category>
		<category><![CDATA[RHT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21876</guid>
		<description><![CDATA[A leading technology software company, Novell Inc. (NOVL) is set to announce its fourth quarter results soon. According to the Zacks Consensus estimates, earnings are expected to be 6 cents a share. Novell expects to maintain double-digit adjusted operating margins for the full year 2009. The company expects the fourth quarter revenue run rate to be slightly below third quarter levels, but also expects the identity business to grow. The company reported mixed third quarter results, with revenue slightly below the Zacks Consensus expectations and adjusted EPS marginally higher. Total revenue declined due to a sharp drop in software license revenue. However, earnings benefited from lower operating expenses due to cost cutting initiatives. Novell has an outsourcing agreement with Affiliated Computer Services Inc. (ACS) and has expanded its partnership with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/novl-earnings-preview-novell/21876/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Settlement in Xerox-Affiliated Computer Services Merger</title>
		<link>http://www.stockbloghub.com/2009/11/25/acs-settlement-in-xerox-affiliated-computer-services-merger/21260</link>
		<comments>http://www.stockbloghub.com/2009/11/25/acs-settlement-in-xerox-affiliated-computer-services-merger/21260#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:38:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21260</guid>
		<description><![CDATA[Affiliated Computer Services Inc. (ACS) announced that the complaint filed by ACS shareholders regarding its merger with Xerox Corp. (XRX) has been resolved. The plaintiffs have temporarily withdrawn their motion for an injunction to block the deal. The lawsuit was filed in October in Dallas County, Texas as Xerox was struggling to convince its shareholders to approve the deal. The plaintiffs agreed to drop the lawsuit only if ACS’s Board of Directors received a better proposal than Xerox’s current bid and Xerox did not force ACS’s Chairman Darwin Deason to exercise his voting power in favor of the Xerox acquisition. The previous agreement called for Mr. Deason to cast half his votes in favor of the Xerox bid. He controls 44% of the votes at ACS. Xerox has also decided ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/acs-settlement-in-xerox-affiliated-computer-services-merger/21260/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NCR) NCR Corporation Rolls Out New Products</title>
		<link>http://www.stockbloghub.com/2009/11/25/ncr-ncr-corporation-rolls-out-new-products/21281</link>
		<comments>http://www.stockbloghub.com/2009/11/25/ncr-ncr-corporation-rolls-out-new-products/21281#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:33:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21281</guid>
		<description><![CDATA[NCR Corporation (NCR) has introduced a patented two-sided thermal (2ST) printing technology standard, to be made available on all NCR SelfServ 20- and 30-series ATMs in North America. This is expected to strengthen NCR’s grip on the self-service ATM market in the region. Management expects the new two-side printer installations to double from the current installed base in retail, financial and other industries. It also stated that the company had secured orders for installations of 2ST printer installations from many North American financial institutions. NCR is also installing the device for BNZ, one of New Zealand’s largest financial institutions. This apart, NCR, in joint collaboration with Evolution Robotics Retail (ERR) announced that ERR’s LaneHawk, used by grocers to eliminate most losses from the basket, will come with NCR Advanced Checkout ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/ncr-ncr-corporation-rolls-out-new-products/21281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Seeks U.S. Food and Drug Administration Approval</title>
		<link>http://www.stockbloghub.com/2009/11/20/azn-astrazeneca-seeks-u-s-food-and-drug-administration-approval/21041</link>
		<comments>http://www.stockbloghub.com/2009/11/20/azn-astrazeneca-seeks-u-s-food-and-drug-administration-approval/21041#comments</comments>
		<pubDate>Fri, 20 Nov 2009 23:31:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21041</guid>
		<description><![CDATA[Recently, AstraZeneca plc (AZN) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its blood clot preventer Brilinta (ticagrelor). Brilinta is an oral reversible P2Y12 adenosine diphosphate receptor antagonist for arterial thrombosis aimed to compete with the blockbuster drug Plavix which is co-developed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY). On Oct 26, 2009, AstraZeneca filed for approval of the drug with the European Medicines Agency (EMEA) and is awaiting validation of the application. AstraZeneca is seeking an FDA approval of Brilinta primarily on the basis of data from PLATO (a study of Platelet Inhibition and Patient Outcomes), a late-stage 18,624 patient trial, that showed that Brilinta was more effective than Plavix in treating patients with acute coronary syndrome (ACS) in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/20/azn-astrazeneca-seeks-u-s-food-and-drug-administration-approval/21041/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Initiating Coverage of Affiliated Computer Services at Neutral</title>
		<link>http://www.stockbloghub.com/2009/11/03/acs-initiating-coverage-of-affiliated-computer-services-at-neutral/19530</link>
		<comments>http://www.stockbloghub.com/2009/11/03/acs-initiating-coverage-of-affiliated-computer-services-at-neutral/19530#comments</comments>
		<pubDate>Tue, 03 Nov 2009 22:16:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19530</guid>
		<description><![CDATA[We are initiating coverage of Affiliated Computer Services Inc. (ACS) with a Neutral rating. Headquartered in Dallas , Texas , ACS delivers IT-based services and solutions globally to commercial and government clients in the U.S. The company is a leading provider of business process outsourcing [BPO], information technology [IT] services and system integration services. With growing revenue Incorporatedreased earnings momentum, strong bookings, cost-control initiatives and substantial free cash flow, we remain positive on the company’s long term prospects. Moreover, we are encouraged by the ramp of new business signings, which were a record for fiscal 2009 at $1 billion of annual recurring revenue (ARR), a substantial increase of 27% from fiscal 2008. Total contract value is estimated at $4.5 billion. While acquisitions have enabled revenue to grow at a considerable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/03/acs-initiating-coverage-of-affiliated-computer-services-at-neutral/19530/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACS) Affiliated Computer Services to Hire Personnel</title>
		<link>http://www.stockbloghub.com/2009/10/15/bpo-affiliated-computer-services-to-hire-personnel/17725</link>
		<comments>http://www.stockbloghub.com/2009/10/15/bpo-affiliated-computer-services-to-hire-personnel/17725#comments</comments>
		<pubDate>Thu, 15 Oct 2009 22:56:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information Technology Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[Cognizant Technology Solutions Corporation]]></category>
		<category><![CDATA[Computer Sciences Corporation]]></category>
		<category><![CDATA[CSC]]></category>
		<category><![CDATA[CTSH]]></category>
		<category><![CDATA[Gartner Inc.]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[XRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17725</guid>
		<description><![CDATA[In order to boost growth in business process outsourcing [BPO] services, Affiliated Computer Services Inc. (ACS) plans to hire 120 employees at its Houston call center. The company also plans to hire approximately 150 people at its Raleigh call center in addition to the 465 additional positions announced in August. Based in Dallas, Affiliated Computer delivers comprehensive BPO and information technology (IT) outsourcing solutions as well as system integration services globally to commercial and government clients. The company’s growing BPO service contributed 84% of fourth quarter revenue, while IT outsourcing contributed 16% of new business signings. Affiliated Computer continues to bank on areas such as ITO, transportation solutions, transactional BPO and government health care, with modest growth in human resources point solutions, state and local government. Moreover, demand for outsourcing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/bpo-affiliated-computer-services-to-hire-personnel/17725/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

